An intensive workshop in the essentials of effective clinical trial designs of therapeutic interventions in the treatment of cancer for clinical fellow and junior faculty clinical researchers in all oncology subspecialties, including radiation and surgical oncology and radiology.
Neal J. Meropol, M.D.
Jamie H. Von Roenn, M.D.
Yu Shyr, Ph.D.
For those protocols using agents from a pharmaceutical company that are not FDA approved for the disease under study, the final application requires a letter of commitment from the collaborating company stating that drug will be supplied for the proposed trial or a copy of the correspondence with the company suggesting their likely support of the trial. Priority will be given to applicants that have a clear letter of support that is uploaded with the application (preferably a letter of commitment, but at minimum, a letter of intent).
Questions?: Please contact Dean Post, Associate Director, Program Development at email@example.com.
Supported by a generous grant from the National Cancer Institute and educational grants from corporate supporters.